CAS 209860-89-9

Tafluprost ethyl ester

Description:

Tafluprost ethyl ester is a synthetic prostaglandin analog primarily used in ophthalmology for the treatment of glaucoma and ocular hypertension. It is a prodrug of tafluprost, which means it is converted into its active form within the body. The compound is characterized by its ability to lower intraocular pressure by increasing the outflow of aqueous humor from the eye. Tafluprost ethyl ester is typically presented as a clear, colorless to pale yellow solution and is soluble in organic solvents. Its mechanism of action involves selective binding to the prostaglandin FP receptor, leading to enhanced uveoscleral outflow. The substance is known for its long duration of action and is often formulated in eye drop preparations. Safety and efficacy profiles have been established through clinical studies, showing it to be effective with a manageable side effect profile, including potential changes in iris pigmentation and eyelash growth. As with any pharmaceutical agent, proper handling and adherence to dosage guidelines are essential for optimal therapeutic outcomes.

Formula: C₂₄H₃₂F₂O₅

Synonyms:

• 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-, ethyl ester, (5Z)-
• SPWJIEVPQKMQPO-MSHHKXPZSA-N
• Tafluprost ethyl ester Exclusive
• Tafluprost ethyl ester

Tafluprost ethyl ester

CAS: 209860-89-9

Tafluprost is a prostaglandin F2-alpha analog that has been shown to be an activator of the human EP4 receptor. Tafluprost binds to the EP4 receptor, which is found in many tissues and cells, including the eye. This binding activates the receptor, which causes increased levels of cAMP and PKA. These increase levels of cAMP and PKA cause vasodilation and reduced intraocular pressure. Tafluprost is used as an ophthalmic medication for the treatment of glaucoma.

Formula: C₂₄H₃₂F₂O₅

Purity: Min. 95%

Molecular weight: 438.5 g/mol

Ref: 3D-JIA86089

Tafluprost ethyl ester

CAS: 209860-89-9

Tafluprost, an analog of prostaglandin F2α (PGF2α) that primarily targets the FP receptor, is employed in glaucoma treatment. Tafluprost (free acid) serves as a potent FP receptor agonist with a Ki value of 0.4 nM. Its derivative, tafluprost ethyl ester, potentially offers enhanced lipid solubility relative to its free acid form, possibly leading to superior tissue absorption and reduced effective concentration requirements.

Formula: C₂₄H₃₂F₂O₅

Color and Shape: Solid

Molecular weight: 438.512

Ref: TM-T84470